Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
Fórmula lineal:
Pt(NH3)2Cl2
Número CAS:
Peso molecular:
300.05
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
239-733-8
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleInChI key
LXZZYRPGZAFOLE-UHFFFAOYSA-L
InChI
1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
SMILES string
N.N.Cl[Pt]Cl
grade
pharmaceutical primary standard
API family
cisplatin
manufacturer/tradename
EDQM
mp
270 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
¿Está buscando productos similares? Visita Guía de comparación de productos
Categorías relacionadas
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Application
This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
- Reference solutions in the identification using infrared absorption spectroscopy and thin-layer chromatography, testing of related substances, and assay using liquid chromatography (General text 2.2.29) of cisplatin, according to the monograph 0599
- Reference solution (b) for the testing of related substances in carboplatin using liquid chromatography (General text 2.2.29), according to the monograph 1081
Biochem/physiol Actions
Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
target_organs
Respiratory system
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hazard Classifications
Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
Clase de almacenamiento
6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Cisplatin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2231-2232 (2009)
Carboplatin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 6104-6105 (2022)
Yi-Long Wu et al.
The Lancet. Oncology, 14(8), 777-786 (2013-06-21)
The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.
Michael F Milosevic et al.
International journal of cancer, 135(7), 1692-1699 (2013-08-02)
Radiotherapy (RT) with concurrent cisplatin (CRT) is standard treatment for locally advanced cervical cancer. However, not all patients benefit from the addition of cisplatin to RT alone. This study explored the value of pretreatment tumor interstitial fluid pressure (IFP) and
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico